Annexon

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Annexon sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 6 completed early-phase tilt upper quartile by trial count

Annexon: 8 sponsored US clinical trials, 1 recruiting.

Annexon sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Geographic Atrophy, with 2 trials.

Upper-quartile sponsor footprint

Annexon sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

NCT07020819
ACTIVE NOT RECRUITING Phase 3

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)

NCT06510816
COMPLETED Phase 2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04691570
COMPLETED Phase 2

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

NCT04656561
COMPLETED Phase 2

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04569435
COMPLETED Phase 2

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

NCT04514367
COMPLETED Phase 1

Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT04188015
COMPLETED Phase 1

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT03488550

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 2

Therapeutic Areas

Geographic Atrophy 2
Open Angle Glaucoma 1
Guillain-Barre Syndrome 1

What is open in the Annexon pipeline

1 recruiting of 8 indexed (13% open); 6 completed (75%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Geographic Atrophy (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Annexon: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Annexon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share AnnexonAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnsun BiopharmaAvidity Biosciences
Annexon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Annexon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Annexon page

8 registered trials is a research-attention snapshot, not an endorsement of Annexon or any single study.

  • 1 of Annexon's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Geographic Atrophy is the condition Annexon studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Geographic Atrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Annexon pipeline card: 8 registered trials from official public datasets.Report a data error.